Live Plague Vaccine Development: Past, Present, and Future
During the last 100 years, vaccine development has evolved from an empirical approach to one of the more rational vaccine designs where the careful selection of antigens and adjuvants is key to the desired efficacy for challenging pathogens and/or challenging populations. To improve immunogenicity w...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/13/1/66 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832587369114501120 |
|---|---|
| author | Andrey P. Anisimov Anastasia S. Vagaiskaya Alexandra S. Trunyakova Svetlana V. Dentovskaya |
| author_facet | Andrey P. Anisimov Anastasia S. Vagaiskaya Alexandra S. Trunyakova Svetlana V. Dentovskaya |
| author_sort | Andrey P. Anisimov |
| collection | DOAJ |
| description | During the last 100 years, vaccine development has evolved from an empirical approach to one of the more rational vaccine designs where the careful selection of antigens and adjuvants is key to the desired efficacy for challenging pathogens and/or challenging populations. To improve immunogenicity while maintaining a favorable reactogenicity and safety profile, modern vaccine design must consider factors beyond the choice of target antigen alone. With new vaccine technologies currently emerging, it will be possible to custom-design vaccines for optimal efficacy in groups of people with different responses to vaccination. It should be noted that after a fairly long period of overwhelming dominance of papers devoted to subunit plague vaccines, materials devoted to the development of live plague vaccines have increasingly been published. In this review, we present our opinion on reasonable tactics for the development and application of live, safe, and protective human plague vaccines causing an enhanced duration of protection and breadth of action against various virulent strains in vaccination studies representing different ages, genders, and nucleotide polymorphisms of the genes responsible for immune response. |
| format | Article |
| id | doaj-art-8b641760934f464cac0f43b764500836 |
| institution | Kabale University |
| issn | 2076-393X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj-art-8b641760934f464cac0f43b7645008362025-01-24T13:51:50ZengMDPI AGVaccines2076-393X2025-01-011316610.3390/vaccines13010066Live Plague Vaccine Development: Past, Present, and FutureAndrey P. Anisimov0Anastasia S. Vagaiskaya1Alexandra S. Trunyakova2Svetlana V. Dentovskaya3Laboratory for Plague Microbiology, Especially Dangerous Infections Department, State Research Center for Applied Microbiology and Biotechnology, 142279 Obolensk, RussiaLaboratory for Plague Microbiology, Especially Dangerous Infections Department, State Research Center for Applied Microbiology and Biotechnology, 142279 Obolensk, RussiaLaboratory for Plague Microbiology, Especially Dangerous Infections Department, State Research Center for Applied Microbiology and Biotechnology, 142279 Obolensk, RussiaLaboratory for Plague Microbiology, Especially Dangerous Infections Department, State Research Center for Applied Microbiology and Biotechnology, 142279 Obolensk, RussiaDuring the last 100 years, vaccine development has evolved from an empirical approach to one of the more rational vaccine designs where the careful selection of antigens and adjuvants is key to the desired efficacy for challenging pathogens and/or challenging populations. To improve immunogenicity while maintaining a favorable reactogenicity and safety profile, modern vaccine design must consider factors beyond the choice of target antigen alone. With new vaccine technologies currently emerging, it will be possible to custom-design vaccines for optimal efficacy in groups of people with different responses to vaccination. It should be noted that after a fairly long period of overwhelming dominance of papers devoted to subunit plague vaccines, materials devoted to the development of live plague vaccines have increasingly been published. In this review, we present our opinion on reasonable tactics for the development and application of live, safe, and protective human plague vaccines causing an enhanced duration of protection and breadth of action against various virulent strains in vaccination studies representing different ages, genders, and nucleotide polymorphisms of the genes responsible for immune response.https://www.mdpi.com/2076-393X/13/1/66<i>Yersinia pestis</i>plague vaccinelive vaccine |
| spellingShingle | Andrey P. Anisimov Anastasia S. Vagaiskaya Alexandra S. Trunyakova Svetlana V. Dentovskaya Live Plague Vaccine Development: Past, Present, and Future Vaccines <i>Yersinia pestis</i> plague vaccine live vaccine |
| title | Live Plague Vaccine Development: Past, Present, and Future |
| title_full | Live Plague Vaccine Development: Past, Present, and Future |
| title_fullStr | Live Plague Vaccine Development: Past, Present, and Future |
| title_full_unstemmed | Live Plague Vaccine Development: Past, Present, and Future |
| title_short | Live Plague Vaccine Development: Past, Present, and Future |
| title_sort | live plague vaccine development past present and future |
| topic | <i>Yersinia pestis</i> plague vaccine live vaccine |
| url | https://www.mdpi.com/2076-393X/13/1/66 |
| work_keys_str_mv | AT andreypanisimov liveplaguevaccinedevelopmentpastpresentandfuture AT anastasiasvagaiskaya liveplaguevaccinedevelopmentpastpresentandfuture AT alexandrastrunyakova liveplaguevaccinedevelopmentpastpresentandfuture AT svetlanavdentovskaya liveplaguevaccinedevelopmentpastpresentandfuture |